BioPharma Credit PLC, an investment trust company, invests in interest-bearing debt assets secured by royalties or other cash flows derived from royalties or sales of approved life sciences products.
Fair value with moderate growth potential.
Share Price & News
How has BioPharma Credit's share price performed over time and what events caused price changes?
Latest Share Price and Events
7 Day Return
US Capital Markets
1 Year Return
US Capital Markets
Return vs Industry: Insufficient data to determine how BOPC.F performed against the US Capital Markets industry.
Return vs Market: Insufficient data to determine how BOPC.F performed against the US Market.
Price Volatility Vs. Market
How volatile is BioPharma Credit's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is BioPharma Credit undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Undervalued: BOPC.F ($1.01) is trading above our estimate of fair value ($0.6)
Significantly Undervalued: BOPC.F is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BOPC.F is good value based on its PE Ratio (10.7x) compared to the Capital Markets industry average (37.3x).
PE vs Market: BOPC.F is good value based on its PE Ratio (10.7x) compared to the US market (17.5x).
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate BOPC.F's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BOPC.F is good value based on its PB Ratio (1x) compared to the US Capital Markets industry average (6.5x).
How is BioPharma Credit forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BOPC.F's forecast earnings growth (23% per year) is above the savings rate (2.7%).
Earnings vs Market: BOPC.F's earnings (23% per year) are forecast to grow faster than the US market (14.4% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if BOPC.F's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if BOPC.F's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: Insufficient data to determine if BOPC.F's Return on Equity is forecast to be high in 3 years time
How has BioPharma Credit performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if BOPC.F's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare BOPC.F's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.
Earnings vs Industry: BOPC.F earnings growth over the past year (137%) exceeded the Capital Markets industry 36.2%.
Return on Equity
High ROE: BOPC.F's Return on Equity (8.2%) is considered low.
Return on Assets
ROA vs Industry: BOPC.F has a higher Return on Assets than the Capital Markets industry average last year.
Return on Capital Employed
ROCE Improving: Insufficient data to calculate BOPC.F's Return on Capital Employed to determine if it has improved over the past 3 years.
How is BioPharma Credit's financial position? (This company is analysed differently as a bank or financial institution)
Financial Position Analysis
Debt to Equity History and Analysis
Inventory Level: BOPC.F has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if BOPC.F's debt is covered by short term assets.
Financial Institutions Analysis
Asset Level: BOPC.F's level of assets compared to its equity is low.
Allowance for Bad Loans: Insufficient data to determine if BOPC.F has a sufficient allowance for bad loans.
Low Risk Liabilities: BOPC.F reports no customer deposits, loans are made up entirely of externally borrowed funds.
Loan Level: Insufficient data to determine if BOPC.F has an acceptable proportion of non-loan assets held.
Low Risk Deposits: BOPC.F has advanced significantly more loans than the customer deposits it holds.
Level of Bad Loans: Insufficient data to determine if BOPC.F has an appropriate level of bad loans.
What is BioPharma Credit's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: BOPC.F's dividend (7.14%) is higher than the bottom 25% of dividend payers in the US market (1.47%).
High Dividend: BOPC.F's dividend (7.14%) is in the top 25% of dividend payers in the US market (3.77%)
Stable Dividend: Whilst dividend payments have been stable, BOPC.F has been paying a dividend for less than 10 years.
Growing Dividend: BOPC.F's dividend payments have increased, but the company has only paid a dividend for 2 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (74.3%), BOPC.F's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
What is the CEO of BioPharma Credit's salary, the management and board of directors tenure and is there insider trading?
Average board tenure
BioPharma Credit has no CEO, or we have no data on them.
Board Age and Tenure
Experienced Board: BOPC.F's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Martin Friedman (54yo)
- Tenure: 0yrs
- Tenure: 0yrs
Pedro Gonzalez de Cosio
- Tenure: 0yrs
Harry Hyman (62yo)
Senior Independent Director
- Tenure: 0yrs
- Compensation: US$70.00k
Duncan Budge (63yo)
- Tenure: 3yrs
- Compensation: US$80.35k
Jeremy Sillem (69yo)
- Tenure: 0yrs
- Compensation: US$100.31k
Colin Bond (58yo)
- Tenure: 2.9yrs
- Compensation: US$92.04k
- Tenure: 0.8yrs
- Compensation: US$5.12k
BioPharma Credit PLC's company bio, employee growth, exchange listings and data sources
- Name: BioPharma Credit PLC
- Ticker: BOPC.F
- Exchange: OTCPK
- Founded: 2016
- Industry: Asset Management and Custody Banks
- Sector: Diversified Financials
- Market Cap: US$1.381b
- Shares outstanding: 1.37b
- Website: https://www.bpcruk.com
- BioPharma Credit PLC
- Beaufort House
- 51 New North Road
- EX4 4EP
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BPCR||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||USD||Mar 2017|
|B3P||MUN (Boerse Muenchen)||Yes||Ordinary Shares||DE||EUR||Mar 2017|
|BPCRL||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||USD||Mar 2017|
|BOPC.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Mar 2017|
BioPharma Credit PLC, an investment trust company, invests in interest-bearing debt assets secured by royalties or other cash flows derived from royalties or sales of approved life sciences products. The c ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/10/15 00:28|
|End of Day Share Price||2019/10/08 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.